3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
1
Metastatic Castration Resistant Prostate Cancer
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Fallopian Tube Neoplasms
1
Interventions
olaparib
4
Bevacizumab
3
niraparib
2
defactinib
2
Paclitaxel
2
Immunoglobulin G
2
Disulfides
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sodium thiosulfate
1
sapanisertib
1
rucaparib
1
relatlimab
1
relacorilant
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
entrectinib
1
durvalumab
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Ovarian Neoplasms
×
rucaparib
×
Clear all
NCT01968213
2023-06-09
ARIEL3
pharmaand GmbH
Phase 3
Completed
564 enrolled
18 charts
1 FDA